Radiology and Oncology (Sep 2015)
Fibulin-3 as a biomarker of response to treatment in malignant mesothelioma
Abstract
Background. Fibulin-3 is a new potential biomarker for malignant mesothelioma (MM). This study evaluated the potential applicability of fibulin-3 plasma levels as a biomarker of response to treatment and its prognostic value for progressive disease within 18 months. The potential applicability of fibulin-3 in comparison with or in addition to soluble mesothelin-related peptides (SMRP) was also assessed.
Keywords